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INTRODUCTION
Oncolytic viral therapy is an investigational cancer treatment that 
has been evaluated in multiple disease settings using a variety of 
viral platforms including adenovirus, herpesvirus, measles virus, 
poxvirus, and others.1 Based on hundreds of patients treated to 
date, this investigational approach has demonstrated a good over-
all safety profile and some strategies have shown signs of efficacy 
in randomized trials. Despite these encouraging results, it is uncer-
tain whether oncolytic viral therapy is sufficiently robust to be 
efficacious when applied as a monotherapy. A major limitation is 
that viruses are immunogenic, and the resulting immune response 
restricts viral persistence and spread, as well as the effectiveness of 
repeated administrations. Although this limitation is desirable from 
a safety standpoint, it may reduce treatment efficacy depending 
on whether the immune response contributes to, or detracts from, 
antitumor activity overall. Hence, it may be necessary to arm such 
viruses with therapeutic genes or combine them with standard 
cancer treatments, or both, to push this promising strategy over the 
therapeutic threshold.
For the past 20 years, we have been developing a multimodal 
approach that utilizes an oncolytic adenovirus platform armed 
with two cytotoxic genes.2–12 We have evaluated the safety and 
potential efficacy of this approach in five clinical trials of prostate 
cancer. The approach has proven to be safe when applied alone or 
in combination with radiotherapy and antitumor activity has been 
demonstrated in multiple disease settings. In a randomized phase 
2 trial, combining oncolytic adenovirus-mediated cytotoxic gene 
therapy with contemporary dose radiotherapy resulted in a 42% 
relative improvement in local tumor control without diminishing 
the patient’s quality of life.10 These encouraging results, and oth-
ers,6,12 lead us to believe that further refinement of this approach 
may ultimately lead to a successful treatment strategy.
Although local tumor control is important, new cancer therapies 
must also target metastatic disease if they are to have an impact 
on survival. Hence, we recently incorporated interleukin 12 (IL-12) 
into our therapeutic platform.13 IL-12 is a proinflammatory cytokine 
produced by antigen presenting cells that stimulates the innate and 
adaptive immune response, inhibits angiogenesis, and reverses the 
immune suppressive nature of the tumor milieu.14–16 Although IL-12 
has exhibited significant antitumor activity in preclinical models, 
its performance in the clinic has been modest largely because of 
severe toxicity when administered systemically.17 Local administra-
tion of IL-12 may circumvent systemic toxicity without diminish-
ing its therapeutic potential. In preparation for a phase 1 trial, we 
examined the toxicity of administering IL-12 intraprostatically via an 
oncolytic, replication-competent adenovirus.
RESULTS
Study design
One hundred and twenty C57BL/6 male mice received 
an injection of saline (n  =  24) or an oncolytic adenovirus 
 (Ad5-yCD/mutTKSR39rep-mIL12) expressing two suicide genes and 
mouse IL-12 (n  =  96). The adenovirus was injected intraprostati-
cally at three dose levels (1.36 × 106, 1.36 × 107, 1.36 × 108 vp/kg) 
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The purpose of this study was to examine the toxicity of combining oncolytic adenovirus-mediated cytotoxic and interleukin 12 
(IL-12) gene therapy in a preclinical model to support future phase 1 trials. One hundred and twenty C57BL/6 male mice received 
an intraprostatic injection of saline (n = 24) or an oncolytic adenovirus (Ad5-yCD/mutTKSR39rep-mIL12) expressing two suicide genes 
and mouse IL-12 (n = 96). The adenovirus was administered at three dose levels (1.3 × 106, 1.3 × 107, 1.3 × 108 vp/kg) followed by 2 
weeks of 5-flurocytosine (5-FC) and gancliclovir (GCV) prodrug therapy. There were no premature deaths. Daily observations of ani-
mals did not reveal any obvious clinical problems throughout the 78-day in-life phase of the study. Animals in the highest adenovi-
rus dose group exhibited lymphopenia and transaminitis on day 3, both of which resolved by day 17. Except for mild inflammation 
of the prostate and seminal vesicles, histopathology of major organs was largely unremarkable. IL-12 and interferon-gamma levels 
in prostate and serum peaked on day 3 and were either undetectable or returned to baseline levels by day 17. No adenoviral DNA 
was detected in serum in any group at any time point. The results demonstrate that local administration of an oncolytic adenovirus 
expressing two suicide genes and IL-12 is well tolerated and support moving this investigational approach into human trials.
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mimicking, on a weight basis, those to be used in future clinical 
trials (Table  1). The adenovirus was also injected intravenously at 
the highest dose level to model a worst case scenario. Two days 
after the adenovirus injection, animals were administered 5-fluro-
cytosine (5-FC)  +  gancliclovir (GCV) prodrug therapy for 2 weeks 
(Figure  1). Animals were observed daily and body weights were 
recorded once per week. Animals (eight per group) were sacrificed 
at three time points representing an early time point (day 3), 1 day 
after completion of the prodrug therapy course (day 17), and a long-
term  endpoint (day 78). The following toxicological parameters 
were examined: complete blood counts (CBCs), liver function tests 
(LFT), and histopathology of 12 major organs (brain, heart, lungs, 
liver, spleen, kidneys, small intestines, large intestines including rec-
tum, urinary bladder, prostate and seminal vesicles, and bone mar-
row) (five animals/group/time point). IL-12, and its major mediator, 
interferon gamma (IFN-γ), were quantified in the injected tissue and 
serum as was adenoviral DNA (three animals/group/time point).
General observations
There were no premature deaths. Daily observation of animals 
did not reveal any obvious clinical problems throughout the 
78-day in-life phase of the study. Body weights increased steadily 
over time for all groups and there was no statistical difference 
in body weights among the groups at any point of the study 
(data not shown).
CBC and LFT
CBC and LFT are shown in Figure 2 and the results are summarized 
in Table 2. Except for lymphocytes (LYMP), alanine aminotransferase 
(ALT), alkaline phosphatase (ALKP), and albumin (ALB), the blood 
chemistries of the investigational groups (groups 1–4) did not dif-
fer significantly from controls (group 5). On day 3, group 3 (highest 
Ad dose, intraprostatic) and group 4 (highest Ad dose, intravenous) 
exhibited lymphopenia. Group 4 also exhibited transaminitis (ALT). 
These events were expected and have been observed in human tri-
als with oncolytic adenoviruses,2–8 as well as trials involving IL-12.17–21
The lymphopenia observed in group 3 (highest Ad dose, intra-
prostatic) on day 3 resolved by day 17. In contrast, the lymphopenia 
observed in group 4 (highest Ad dose, intravenous) took longer to 
resolve; however, it was within normal limits by the end of the study 
(day 78). The transaminitis observed in group 4 (highest Ad dose, 
intravenous) on day 3 resolved by day 17.
Group 4 (highest Ad dose, intravenous) also exhibited decreased 
ALKP on day 17 and increased ALB on day 78. The former event was 
likely because of hemolysis of the blood samples.22 The basis for the 
slight increase in ALB on day 78 is unknown but is not considered 
clinically significant, as all other liver enzymes were within normal 
limits.
IL-12 and IFN-γ levels in injected tissue and serum
IL-12 and IFN-γ were quantified in prostate and serum at each of the 
three time points. IL-12 levels in prostate increased with the adeno-
virus dose and reached 1,328 pg/g in the highest dose (group 3) 
on day 3 (Table 3). At this time point, IL-12 levels in prostate were 
15-fold higher than that of serum. Peak IL-12 levels in serum (90.3 
pg/g or pg/ml) were well below the range (6,000–20,000 pg/ml) 
reported in humans that were administered IL-12 systemically at 
the maximum tolerated dose of 500 ng/kg.17,18 On days 17 and 78, 
IL-12 was undetectable in prostate and within the range of controls 
(group 5) in serum.
IFN-γ, which mediates IL-12’s antitumor activity and toxicity, was 
detectable only in prostate at the highest adenovirus dose on day 3 
(Table 3). It was undetectable in the prostate on days 17 and 78. No 
IFN-γ was detected in serum at any time point.
Adenoviral DNA in injected tissue and blood
Ad5-yCD/mutTKSR39rep-mIL12 DNA was quantified by poly-
merase chain reaction (PCR) in both injected tissue and blood. 
 Ad5-yCD/mutTKSR39rep-mIL12 DNA was detected in the prostate 
of animals injected intraprostatically and increased with adenovi-
rus dose (not shown). No Ad5-yCD/mutTKSR39rep-mIL12 DNA was 
detected in blood at any time point.
Histopathology of major organs
Twelve organs were subjected to histopathological analysis at each 
of the three time points. Except for prostate and seminal vesicles, 
urinary bladder, liver, spleen, and bone marrow, there were no 
notable changes (from controls) throughout the life of the study. As 
expected, animals that were administered the adenovirus intrapros-
tatically (groups 1–3) exhibited acute inflammation of the prostate 
Table 1 Study cohorts
Group Number
Route of  
administration
Adenovirus 
dose vp  
(vp/kg)
Human  
equivalent  
dosea vp (vp/kg)
1 24 Intraprostatic 3 × 106 
(1.28 × 108)
1 × 1010 
(1.25 × 108)
2 24 Intraprostatic 3 × 107 
(1.28 × 109)
1 × 1011 
(1.25 × 109)
3 24 Intraprostatic 3 × 108 
(1.28 × 1010)
1 × 1012 
(1.25 × 1010)
4 24 Intravenous 3 × 108 
(1.28 × 1010)
1 × 1012 
(1.25 × 1010)
5 24 Intraprostatic Saline NA
aAssuming 80 kg (175 lbs.) human. Mean weight of 120 mice at the time of 
adenovirus injection was 23.4 g.
Figure 1  Study design. Mice received an injection of saline or  Ad5-
yCD/mutTKSR39rep-mIL12 on day 1 as described in the text. Animals that 
were administered the adenovirus also received 5-FC + GCV prodrug 
therapy for 2 weeks beginning on day 3. Eight animals in each group 
were sacrificed on days 3, 17, and 78 and CBC, LFT, and histopathology of 
12 major organs were examined (five mice/group/time point). IL-12,  IFN-
γ and adenoviral DNA were quantified in the injected tissue and serum 
(three mice/group/time point).
Inject
adenovirus
5-FC + GCV
CBC, LFT, Histopathology, IL-12, IFN-γ, adenoviral DNA
1
Day
3 1617 78
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Figure 2 CBC and LFT Each data point represents the mean of five animals ± the standard deviation. WBC, white blood cells; RBC, red blood cells; HGB, 
hemoglobin; ALKP, alkaline phosphatase; ALT, alanine aminotransferase, AST, aspartate aminotransferease. Group 1, 3 × 106 vp intraprostatic; group 2, 
3 × 107 vp intraprostatic; group 3, 3 × 108 vp intraprostatic; group 4, 3 × 108 vp intravenous; group 5, saline intraprostatic.
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and seminal vesicles on day 3 that increased with adenovirus dose 
(Table 4). Some of this inflammation could be attributed to the injec-
tion procedure itself as animals in the control group (group 5) also 
exhibited acute inflammation. The inflammation became chronic at 
the latter time points and essentially resolved (equal to controls) by 
the end of the study. Focal, mixed cell infiltrates without necrosis 
were observed in liver on day 3 and, as expected, was greatest in 
animals that received the adenovirus intravenously (group 4). Such 
infiltrates were less frequent in animals that received the adenovirus 
intraprostatically (groups 1–3) and all resolved (equal to controls) 
by the end of the study. Mixed cell inflammation and hemato-
poietic cell proliferation were observed in spleen on day 17 of all 
groups administered the adenovirus (groups 1–4). These events did 
not correlate with adenovirus dose and resolved by the end of the 
study. Bone marrow hypercellularity was also observed on day 17 
in animals receiving the adenovirus intraprostatically (but not intra-
venously). Much like the spleenic events, these events did not cor-
relate with adenovirus dose and resolved by the end of the study.
Comparison of IL-12 gene expression and biological effects in 
mouse versus human tissue
A limitation of the mouse model is that human adenoviruses do 
not produce a significant viral burst in mouse cells, although they 
do support adenoviral DNA replication.22 To extrapolate our find-
ings in the mouse to the human setting, we (i) quantified IL-12 gene 
expression in mouse and human prostate epithelial cells following 
infection with Ad5-yCD/mutTKSR39rep-IL12 and (ii) compared the 
biological potency of mouse versus human IL-12.
Normal and malignant mouse and human prostate epithelial 
cells were infected with adenovirus expressing either mouse (Ad5-
yCD/mutTKSR39rep-mIL12) or human  (Ad5-yCD/mutTKSR39rep-hIL12) 
IL-12, and IL-12 production was quantified at multiple times there-
after. In all cell types, IL-12 expression increased with time (Figure 3). 
Seventy-two hours after infection, the amount of IL-12 produced 
was approximately two- (normal) to fourfold (malignant) greater in 
human versus mouse cells. This assay measures together the rela-
tive infectivity, DNA replication, and viral transgene expression in 
human versus mouse cells. Thus, for a given adenovirus dose (vp/
kg), we expect that the human prostate will generate about two- to 
fourfold more IL-12 than the mouse prostate.
Finally, we compared the relative biological potency of mouse 
versus human IL-12. Since mouse IL-12 binds efficiently to the 
human IL-12 receptor (but not vice versa), we used human periph-
eral blood mononuclear cells (PBMCs) as targets to limit the num-
ber of variables in the study (i.e., the source of IL-12) to one. Human 
PBMCs were incubated with increasing amounts of IL-12 produced 
from Ad5-yCD/mutTKSR39rep-mIL12 or Ad5-yCD/mutTKSR39rep-hIL12 
and IFN-γ production and cell proliferation were measured 72 
hours later. Over all IL-12 concentrations examined (0–1,000 pg/
ml), the biological potency of mouse and human IL-12 differed by 
less than twofold (Figure 4). At the IL-12 concentration detected in 
mouse serum on day 3 (90.3 pg/ml, see Table 3), IFN-γ production 
and cell proliferation were essentially identical. We conclude that 
the biological potency of mouse and human IL-12 is similar.
DISCUSSION
IL-12 has been investigated as a potential cancer treatment for 
~15 years. Although it has exhibited significant antitumor activ-
ity in preclinical models, its activity in the clinic has been modest 
(<11% tumor response rate) largely because of severe toxicity when 
Table 2 Clinical chemistries
Parameter Group affected Values P value
All investigational groups (groups 1–4) versus control (group 5)
Day 3
LYMP group 3 < group 5 2.22 ± 0.36 versus 3.84 ± 0.52 0.030
group 4 < group 5 2.05 ± 0.62 versus 3.84 ± 0.52 0.014
ALT group 4 > group 5 29 ± 6 versus 13 ± 3 < 0.001
Day 17
LYMP group 4 < group 5 2.54 ± 1.20 versus 4.20 ± 0.42 0.021
ALKP group 4 < group 5 34 ± 16 versus 76 ± 8 < 0.001
Day 78
ALB group 4 > group 5 1.7 ± 0.1 versus 1.4 ± 0.1 0.032
Highest dose intraprostatic (group 3) versus highest dose intravenous 
(group 4)
Day 3
ALT group 3 < group 4 14 ± 3 versus 29 ± 6 < 0.001
Day 17
LYMP group 3 > group 4 4.32 ± 0.61 versus 2.54 ± 1.20 0.012
ALKP group 3 > group 4 73 ± 14 versus 34 ± 16 0.001
Day 78
ALT group 3 < group 4 13 ± 2 versus 20 ± 3 0.025
ALB group 3 < group 4 1.4 ± 0.1 versus 1.7 ± 0.1 0.002
ALB, albumin; ALT, alanine aminotransferase; ALKP, alkaline phosphatase; 
LYMP, lymphocytes.
Table 3 IL-12 and IFN-γ levels in injected tissue and serum.
Group
Injected tissue Seruma
Day Day
3 17 78 3 17 78
IL-12 (pg/g)
1 0b 0 0  7.2 ± 1.3  2.8 ± 2.8  2.1 ± 3.4
2  14.7 ± 7.1 0 0  6.3 ± 3.4  2.3 ± 2.2  1.7 ± 1.6
3 1,328 ± 59 0 0 90.3 ± 19.7  1.9 ± 1.7  1.9 ± 3.4
4 Ad injected 
intravenously-see serum
 6.9 ± 9.9 11.2 ± 19.4  1.8 ± 2.5
5 0 0 0  3.8 ± 3.6  1.9 ± 3.4  2.9 ± 2.5
IFN-γ (pg/g)
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 174.2 ± 26 0 0 0 0 0
4 Ad injected 
intravenously-see serum
0 0 0
5 0 0 0 0 0 0
aAssumes density of mouse serum is 1.024 g/ml. bAll values of zero were 
below the limit of detection of the ELISA (7.8 pg/ml for both IL-12 and IFN-γ).
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administered systemically. In an attempt to circumvent this limita-
tion, we and others have examined the merit of administering IL-12 
locally (ref. 13, for reviews see refs. 14–16). Intratumoral administra-
tion of Ad5-yCD/mutTKSR39rep-mIL12 improved both local and meta-
static tumor control in a preclinical model of prostate cancer. These 
effects were accompanied by increased natural killer and cytotoxic 
T lymphocyte activity, both of which were required for IL-12’s anti-
tumor effects. We report here that intraprostatic administration 
of Ad5-yCD/mutTKSR39rep-mIL12 at doses to be used in human tri-
als (on a vp/kg basis) was associated with low systemic toxicity. 
Although animals in the highest adenovirus dose group developed 
transaminitis, lymphopenia, and inflammation of the prostate/sem-
inal vesicles, these adverse events were expected, low grade, and 
transient. Overall, our preclinical data support moving this investi-
gational therapy into the clinic.
A limitation of the mouse model is that mouse cells do not sup-
port the productive replication of human adenoviruses (i.e., they 
do not generate a significant viral burst). Hence, when examin-
ing the toxicity of oncolytic adenoviruses, the mouse model may 
underestimate the toxicity that will occur in humans. Although 
other animal species (e.g., Syrian hamster) support the produc-
tive replication of human adenoviruses containing a wild-type E1 
region,24 we have found that the replication of 55 kDa E1B-deleted 
adenoviruses, such as Ad5-yCD/mutTKSR39rep-mIL12, is markedly 
attenuated (by  ~100-fold) in the Syrian hamster relative to wild-
type Ad5 (unpublished results). Because we have demonstrated 
the safety of administering oncolytic adenoviruses without IL-12 to 
humans in five clinical trials of prostate cancer,4–10 our major con-
cern here was not the toxicity of the oncolytic adenovirus and/
or suicide gene therapy, but the increased toxicity because of the 
addition of IL-12. Owing to the fact that human IL-12 is not active 
in the mouse,25 we could not use an adenovirus expressing human 
hIL-12 (i.e.,  Ad5-yCD/mutTKSR39rep-hIL12) for these studies and, 
instead, elected to use an adenovirus expressing mouse IL-12 (i.e., 
Ad5-yCD/mutTKSR39rep-mIL12). However, the biological activity of 
mouse IL-12 in the Syrian hamster is not known. Therefore, we chose 
to conduct these studies in the mouse so that the host would match 
the variant of IL-12 contained in injected adenovirus. We acknowl-
edge that the viral burst obtained in human cells may heighten 
the immune response and exacerbate toxicity when combined 
with IL-12. Hence, patients in our upcoming clinical studies may 
exhibit greater inflammation of the prostate and other immune-
related toxicities than what was observed here in the mouse stud-
ies. We demonstrate that human prostate epithelial cells express 
only approximately two- (normal) to fourfold (malignant) more 
IL-12 than mouse prostate epithelial cells following infection with 
an oncolytic adenovirus expressing IL-12. This modest difference is 
likely attributable to the fact that mouse prostate epithelial cells are 
readily infectable by human adenovirus and support viral DNA rep-
lication (although they do not generate a viral burst).23 We also dem-
onstrate that mouse IL-12 has roughly the same biological potency 
(on a mass basis) as human IL-12. Thus, when considering the toxic-
ity because of the addition of IL-12, we believe the mouse model is 
as good as any and is likely to recapitulate many of the events that 
will occur in humans.
Ad5-yCD/mutTKSR39rep-mIL12 (and Ad5-yCD/mutTKSR39rep-
hIL12) has the same viral tropism as the three oncolytic adeno-
viruses we have studied earlier. Because the biodistribution 
of these adenoviruses was examined in preclinical models 
and humans,8,9,22 there was no need to examine the biodis-
tribution of  Ad5-yCD/mutTKSR39rep-mIL12 here. Using an 
oncolytic adenovirus (Ad5-yCD/mutTKSR39rep-hNIS) similar to 
 Ad5-yCD/mutTKSR39rep-hIL12 that can be imaged noninvasively, 
we demonstrated earlier in humans that the vast majority of the 
injected adenovirus remains in the prostate following intrapros-
tatic administration.8,9 No extraprostatic gene expression was 
detected in 18 patients treated, 6 of whom were administered 
5 × 1012 vp (6.25 × 1010 vp/kg) or five times the highest dose (on 
a weight basis) used here. Our human imaging results must be 
interpreted cautiously owing to the insensitivity of the imaging 
procedures (lower limit of detection is ~3 × 1011 vp in humans) 
and the fact that roughly half of patients develop low grade flu-
like symptoms and transaminitis. We believe these latter events 
are because of a low level of adenovirus dissemination beyond 
the prostate gland. Because systemic administration of IL-12 can 
result in severe toxicity,17 it will be important to limit extraprostatic 
Table 4 Notable histopathological findings
Group
Day
3 17 78
1 Prostate 
and SV, 2.0
Prostate and SV, 0.6 Prostate and SV, 0.2
Liver, 0.4 Liver, 0.3
Bladder, 0
Liver, 0 Spleen, 0.4 Spleen, 0
Bladder, 0 Bone marrow, 1.6 Bone marrow, 0
2 Prostate 
and SV, 2.4
Prostate and SV, 0.7 Prostate and SV, 0.4
Liver, 0.8 Liver, 0.3
Bladder, 0
Liver, 0.4 Spleen, 0.3 Spleen, 0.2
Bladder, 0 Bone marrow, 1.2 Bone marrow, 0
3 Prostate 
and SV, 2.6
Prostate and SV, 0.8 Prostate and SV, 0.2
Liver, 0.4
Bladder, 0 Liver, 0.4
Liver, 0.2 Spleen, 0.3 Spleen, 0.2
Bladder, 0.4 Bone marrow, 1.4 Bone marrow, 0
4 Prostate 
and SV, 1.2
Prostate and SV, 0.1 Prostate and SV, 0
Liver, 0.2 Liver, 0.3
Bladder, 0
Liver, 1.0 Spleen, 0.6 Spleen, 0
Bladder, 0 Bone marrow, 0 Bone marrow, 0
5 Prostate 
and SV, 2.0
Prostate and SV, 0.1 Prostate and SV, 0.2
Liver, 0.6
Bladder, 0 Liver, 0.3
Liver, 0.4 Spleen, 0.1 Spleen, 0.2
Bladder, 0 Bone marrow, 1.0 Bone marrow, 0
SV, seminal vesicles. Numbers represent the mean histopathological score of 
five animals with 1 representing minimal change and 5 representing severe 
change. The following pathologies were noted: prostate, seminal vesicles, 
and bladder—acute inflammation (day 3) that became chronic (or resolved) 
at the latter time points; liver—focal, mixed cell infiltrate without necrosis; 
spleen—mixed cell inflammation and hematopoietic cell proliferation; bone 
marrow—hypercellularity.
6Toxicology of combined suicide and IL-12 gene therapy
SO Freytag et al.
Molecular Therapy — Oncolytics (2015) 15006 © 2015 The American Society of Gene & Cell Therapy
dissemination of Ad5-yCD/mutTKSR39rep-hIL12 in future trials. We 
believe this can be accomplished by carefully controlling the vol-
ume, dose, and placement of the adenovirus deposits within the 
prostate gland.
In summary, we have demonstrated in a preclinical model that 
intraprostatic administration of an oncolytic adenovirus expressing 
two cytotoxic genes and IL-12 at doses to be used in humans is asso-
ciated with low toxicity. These results, and others,13 support moving 
this investigational treatment into the clinic for further evaluation.
MATERIALS AND METHODS
Adenovirus and cell lines
Ad5-yCD/mutTKSR39rep-mIL12 has been described earlier.
13 In brief, it is a 
55 kDa E1B-deleted replication-competent adenovirus that contains a yeast 
cytosine deaminase (yCD)/mutant SR39 herpes simplex virus thymidine 
kinase (mutTKSR39) fusion gene in the E1 region and a single-chain murine 
IL-12 gene in the E3 region. Both the yCD/mutTKSR39 fusion gene and IL-12 
genes are under the transcriptional control of the human cytomegalovirus 
promoter. Ad5-yCD/mutTKSR39rep-mIL12 was propagated in human embry-
onic kidney (HEK) 293 cells and was free of contaminating wild-type adeno-
virus based on PCR. The viral particle (vp) to plaque-forming unit ratio of the 
Ad5-yCD/mutTKSR39rep-mIL12 preparation used in the toxicology study was 
18. HEK 293, DU145, TRAMP-C2, and primary human prostate epithelial cells 
(PCS-440-010) were obtained from the American Type Culture Collection 
(Manassas, VA). Mouse (C57BL/6) primary prostate epithelial cells (C57-6038) 
were obtained from Cell Biologics, Inc (Chicago, IL). All cell lines were main-
tained in medium recommended by the supplier.
Toxicology study
One hundred and twenty C57BL/6 male mice (22–24 g) were administered 
an intraprostatic injection of saline (n = 24) or  Ad5-yCD/mutTKSR39rep-mIL12 
(n = 72) at one of three dose levels (1.3 × 106, 1.3 × 107, 1.3 × 108 vp/kg) on day 
1. To model a worst case scenario, 24 mice were administered the adenovirus 
intravenously at the highest dose level (1.3 × 108 vp/kg). The volume of the 
adenovirus injection was 10 µl. Animals that were administered adenovirus 
also received daily intraperitoneal injections (1 ml) of 5-FC (500 mg/kg) and 
GCV (30 mg/kg) for 2 weeks beginning on day 3.
Figure 3 IL-12 production in mouse versus human prostate epithelial cells. Normal and malignant mouse and human prostate epithelial cells were 
infected with Ad5-yCD/mutTKSR39rep-IL12 and IL-12 production was measured by ELISA at various times thereafter as indicated. The bars represent 
the mean of three independent determinations ± SD. Primary cultures of mouse (C57BL/6) and human prostate epithelial cells were used for normal 
cells. TRAMP-C2 and DU145 cells were used for malignant mouse and human prostate epithelial cells, respectively. Shown are results with  Ad5-
yCD/mutTKSR39rep-hIL12 (expressing human IL-12). Ad5-yCD/mutTKSR39rep-mIL12 (expressing mouse IL-12) gave essentially identical results.
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Figure 4 Relative biological potency of mouse versus human IL-12. Human PBMCs were incubated with increasing amounts of IL-12 produced from 
Ad5-yCD/mutTKSR39rep-mIL12 (expressing mouse IL-12) or Ad5-yCD/mutTKSR39rep-hIL12 (expressing human IL-12) and IFN-γ production (left) and cell 
proliferation (right) were measured 72 hours later. For human IL-12, both laboratory grade and clinical grade adenovirus was examined. Each data point 
represents the mean of three independent determinations with SD <5%. IFN-γ production with no added IL-12 was 3.2 pg/ml.
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Animals were observed daily for any clinical problems (weight loss, 
listlessness, hunching, and poor grooming) and observations were docu-
mented. Body weights were recorded once per week. Animals (eight per 
group) were sacrificed at three time points representing an early time point 
(day 3), 1 day after completion of the prodrug therapy course (day 17), and a 
long-term endpoint (day 78). Blood was collected by single stick of the cau-
dal vena cava, and all blood that spilled into the abdomen was collected.26 
The following toxicological parameters were examined: CBCs, LFTs, and his-
topathology of 12 major organs (brain, heart, lungs, liver, spleen, kidneys, 
small intestines, large intestines including rectum, urinary bladder, pros-
tate and seminal vesicles, and bone marrow) (five mice/group/time point). 
Gross observations at necropsy were recorded on study-specific necropsy 
forms. Tissues (except blood) were immediately fixed in 10% (v/v) neutral 
buffered formalin until processed for histopathology. IL-12 and IFN-γ were 
quantified in the injected tissue and serum by enzyme-linked immunosor-
bent assay (ELISA) (R&D Systems, Minneapolis, MN) (three mice/group/time 
point). Adenoviral DNA in blood was quantified by PCR (three mice/group/
time point). Histopathology was conducted by Dr. John Seely (Experimental 
Pathology Laboratories; Herdon, VA). CBC and blood chemistries were 
analyzed by Antech GLP (Morrisville, NC). The study was conducted under 
Institutional Animal Care and Use Committee (IACUC)-approved protocol 
1137 and monitored by an independent study monitor.
IFN-γ production and cell proliferation assays
Human PBMCs were isolated on Histopaque 1077 gradients per the manu-
facturer’s protocol. PBMCs were washed twice with saline and stimulated 
with phytohemagglutinin-M (1.5% v/v) for 3 days in medium containing 
10% fetal bovine serum. Cells were washed, counted, and incubated in 96 
well round-bottomed plates (IFN-γ assays—100,000 cells/well; proliferation 
assays—12,500 cell/well) with increasing amounts of conditioned media from 
DU145 cells infected with Ad5-yCD/mutTKSR39rep-mIL12 (expressing mouse 
IL-12) or Ad5-yCD/mutTKSR39rep-hIL12 (expressing human IL-12). The IL-12 con-
centration in the conditioned media was quantified by ELISA prior to setting 
up the assays. Conditioned media from mock-infected cells served as a base-
line control. IFN-γ production was quantified by ELISA, and cell proliferation by 
Vybrant MTT pulse assay (Life Technologies, Grand Island, NY), 72 hours later.
Statistical methods
Blood values of all groups were compared by ANOVA using SigmaPlot 
v12.3. A blood value was considered abnormal if it was statistically different 
(P < 0.05) than the control group (group 5) at the same time point.
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